Abramson Cancer Center Support Grant

 描述(由申请人提供)：免疫生物学专业旨在：1)了解免疫生物学的基本方面，包括与癌症相关的激活、分化、失活和转化；2)利用最先进的体外、动物模型和人体实验系统，全面了解肿瘤免疫监测；以及3)通过设计、实施和分析概念验证人体临床试验，翻译癌症免疫治疗的新临床策略。该研究计划成立于1974年，在上一次CCSG续签申请时获得了“杰出”荣誉。该计划由罗伯特·冯德海德医学博士、肿瘤免疫学和免疫疗法专家DPhil和白细胞发育和恶性转化分子生物学专家Warren Pear医学博士共同领导。冯德海德博士和皮尔博士都是经验丰富的、由NCI资助的研究人员，他们高度合作，他们的研究兴趣横跨基础科学和翻译科学领域。有来自10个部门和4所学校的34名计划成员，他们在基础和临床计划方面有着长期的计划内和计划间合作。通过这些互动，成员的集体专业知识成为寻求跨学科方法来解决关于癌症的免疫生物学和免疫疗法的基本问题的丰富资源。成员包括基础免疫学、肿瘤免疫生物学和转化免疫疗法方面的国家领导者。该计划的共同领导人通过每周多个研讨会和会议、促进合作赠款和项目、年度研究务虚会、试点项目赠款和培训计划来促进互动。在本项目期间，方案领导人招募了新成员，扩大了重要论坛，促进了新的协作赠款，发起了新的行政协调会倡议，并积极参与关于新的和现有的共享资源的决策。目前，项目成员有2060万美元的研究拨款(年度直接成本)，其中1130万美元是同行评审，220万美元是NCI资助的。在本项目期间，方案成员发表了421份与癌症有关的出版物，其中许多发表在该领域的顶级期刊上。其中，17%是计划内计划，24%是计划间计划，29%是多机构计划。

 DESCRIPTION (provided by applicant): The Immunobiology Program aims to: 1) Understand the fundamental aspects of immune biology, including activation, differentiation, inactivation, and transformation as these relate to cancer; 2) Forge a comprehensive understanding of tumor immune surveillance using state-of-the art in vitro, animal model, and human experimental systems; and 3) Translate novel clinical strategies for immunotherapy of cancer by the design, implementation, and analysis of proof-of-concept human clinical trials. Established in 1974, this Research Program received "Outstanding" merit at the time of the last CCSG renewal application. The Program is Co-Led by Robert Vonderheide, MD, DPhil, an expert in tumor immunology and immunotherapy, and Warren Pear, MD, PhD, an expert in the molecular biology of leukocyte development and malignant transformation. Drs. Vonderheide and Pear are experienced, NCI-funded investigators who are highly collaborative and whose research interests span the realm of basic and translational science. There are 34 Program members from 10 departments and four schools with long-standing intra- and inter-Programmatic collaborations spanning the Basic as well as Clinical Programs. Through these interactions, the members' collective expertise serves as a rich resource for the pursuit of interdisciplinary approaches to fundamental questions about the immunobiology and immunotherapy of cancer. Members include national leaders in basic immunology, tumor immunobiology and translational immunotherapy. The Program Co-Leaders facilitate interactions through multiple weekly seminars and meetings, promotion of collaborative grants and projects, an annual research retreat, Pilot Project grants, and training programs. During the current project period, Program Leaders recruited new members, expanded important forums, facilitated new collaborative grants, initiated new ACC-wide initiatives, and were actively involved in decisions regarding new and existing Shared Resources. Currently, Program members have $20.6M in research grant funding (annual direct costs), of which $11.3M is peer-reviewed and $2.2M is NCI-funded. During the current project period, Program members published 421 cancer-related publications, many of which are in top journals in the field. Of these, 17% are intra-Programmatic, 24% are inter-Programmatic, and 29% are multi-institutional.